默克集团等3家全球顶尖药企落户 香港重点企业总数破百家 中新社香港10月9日电 香港特区政府引进重点企业办公室(简称"引进办")9日在特区政府总部举行新一批 重点企业签约仪式。新一批共18家重点企业落户香港，包括3家全球十大医药企业。 10月9日，由香港特区政府引进重点企业办公室举办的重点企业签约仪式在香港特区政府总部举 行。图为重点企业签约仪式。 中新社记者 李志华 摄 引进办主任任景信表示，顶尖药企的落户将有助推动香港成为临床研究及创新药物开发的重要基地。新 一批重点企业亦创下另一项纪录——高达40%的企业来自海外，反映香港作为国际大都会的吸引力持续 增强，深受全球创科企业青睐。(完) 来源：中国新闻网 编辑：熊思怡 广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview")，看更多精彩财经资讯。 引进办表示，随着该批企业加入，引进办的重点企业伙伴总数正式突破100家。这些重点企业预计为香 港带来约600亿港元投资，并创造约22000个就业职位，为经济 ...

Core Viewpoint - Jinfang Pharmaceutical (2595.HK) officially listed on the Hong Kong Stock Exchange on September 19, raising a total of $268 million, marking the largest fundraising in the Hong Kong 18A sector since 2022 [1][3] Company Overview - Jinfang Pharmaceutical is a globally positioned innovative drug development company focusing on unmet clinical needs in oncology and immune-related diseases, leveraging disease biology mechanisms and clinical translational medicine [6] - The company has established a comprehensive R&D system with multiple proprietary "global new" projects, entering global multi-center clinical trials in China, Europe, and the United States since its establishment in 2017 [6] IPO Details - The IPO raised $233 million before the exercise of the over-allotment option, which increased the total to $268 million, with cornerstone investors contributing $100 million [1][3] - The company was exclusively sponsored by CITIC Securities for this IPO [1] Product Pipeline - The company’s first approved product, Daberu (Fluorazeres), is the first KRAS G12C inhibitor approved in China and the third globally, with a comprehensive RAS-targeted therapy matrix developed [3][6] - Jinfang has completed the development of multiple selective and pan-RAS inhibitors, with several products leading in development speed both domestically and internationally [4][6] Clinical Research and Innovations - The company is advancing multiple original products, including GFH375, an oral KRAS G12D inhibitor, which is in the first tier of development for treating pancreatic cancer and non-small cell lung cancer [4] - The KROCUS study is the first global trial for KRAS+EGFR first-line treatment of non-small cell lung cancer, while GFS202A is the first clinical-stage dual antibody therapy for cachexia [5] Strategic Partnerships and Collaborations - Since 2021, Jinfang has engaged in licensing agreements with several domestic and international companies, including Innovent Biologics and Verastem Oncology, enhancing its commercial collaboration network [3][6] - The company has received various national and local recognitions, including being named a "Little Giant" enterprise and a high-tech enterprise, reflecting its innovation and growth potential [6]

Core Viewpoint - Jinfang Pharmaceutical-B plans to globally offer 77.6 million H-shares, with approximately 10% allocated for public offering in Hong Kong and 90% for international offering, at a price of HKD 20.39 per share, expected to be listed on September 19, 2025 [1] Group 1: Company Overview - Jinfang Pharmaceutical is an innovative drug development company with a global vision and operational capability, having one innovative drug already approved [1] - The company's vision is to become a globally competitive biopharmaceutical company [1] Group 2: Product Pipeline - The company has established a pipeline consisting of eight candidate products, with five currently in clinical development [1] - One of the core products, GFH925 (Dabert), has been approved in China for the treatment of advanced non-small cell lung cancer (NSCLC) [1] - The company is also exploring therapies for autoimmune diseases, inflammatory diseases, and cancer-related conditions [1] Group 3: Fundraising and Use of Proceeds - The net proceeds from the global offering are expected to be approximately HKD 1.4436 billion [1] - About 71% of the proceeds will be used for the further development of core products GFH925 and GFH375 [1] - Approximately 19% will be allocated for the development of other candidate products, including GFH312 [1] - About 10% will be used for working capital and general corporate purposes [1] Group 4: Strategic Partnerships - The company has signed agreements with several cornerstone investors, including RTW Fund, TruMed, UBS Asset Management, Huatai PineBridge Fund, CITIC Securities International Capital Management, and Qingchi entities [1]

Core Viewpoint - Johnson & Johnson (JNJ.US) has decided to terminate the joint development project of its experimental antibody drug, nipocalimab, with anti-tumor necrosis factor alpha (anti-TNFα) therapy for the treatment of rheumatoid arthritis (RA) due to the results of its Phase 2a DAISY proof-of-concept study, which showed no significant clinical benefits over the use of anti-TNFα therapy alone [1] Group 1 - The combination therapy of nipocalimab and anti-TNFα did not demonstrate significant clinical benefits in RA patients compared to anti-TNFα therapy alone, despite no new safety issues being reported [1] - Johnson & Johnson has decided not to advance the clinical development of this combination therapy in the RA treatment area based on the study findings [1] - Nipocalimab was previously considered a key research project in Johnson & Johnson's rheumatology portfolio, with projected peak annual sales exceeding $5 billion [1] Group 2 - The setback highlights the high-risk nature of innovative drug development, particularly in the competitive field of autoimmune disease treatments [1] - Humira, AbbVie's blockbuster drug, generated nearly $21 billion in sales in 2021 but is facing sales pressure starting in 2023 due to the introduction of biosimilars by U.S. companies [1]

Summary of the Conference Call for Dize Pharmaceutical Company Overview - **Company**: Dize Pharmaceutical - **Key Products**: Shuorze (舒尔哲), 8,586, 6,008, and Grixotin (格力西替尼) Industry Insights - **FDA Approvals**: Shuorze received accelerated approval from the FDA, becoming the first oral EGFR TKI for small cell lung cancer with an insertion of easy-to-interact factor 20, gaining significant market advantage [2][3] - **Market Position**: 8,586 is the first dual-pathway BTK inhibitor globally, showcasing promising results in CLL and SLL treatments at the ASCO conference [2][3] Financial Performance - **Revenue Growth**: In the first half of 2025, Dize Pharmaceutical's revenue increased by 74% year-on-year to 355 million RMB, with a sales expense ratio reduction of approximately 24% [2][5] - **Cash Reserves**: The company successfully raised nearly 1.8 billion RMB through refinancing, increasing cash reserves to 2.251 billion RMB, alleviating investor concerns about cash flow [2][6] Key Milestones - **Shuorze Developments**: - Approved by the FDA in July 2025 and included in the NCCN guidelines shortly after [3][7] - Ongoing Phase III registration studies to meet FDA requirements [8] - **8,586 Developments**: - Demonstrated significant efficacy in DLBCL patients, with an objective response rate (ORR) of 84.2% in frontline treatment failure patients [16] - Fast track designation from the FDA based on clinical results [18] - **6,008 Developments**: - Showed significant effects on resistant EGFR mutations, with over 50 times selectivity against wild-type EGFR [19] - Currently progressing towards registration clinical trials with over 100 patients enrolled [30] Research and Development - **Pipeline Projects**: - GW5,282 is in the dose escalation phase, showing potential in both hematological and solid tumors [23][25] - Grixotin is undergoing multiple Phase II clinical trials to determine first-line treatment strategies [24][32] - **Clinical Trials**: - Multiple Phase III trials are set to begin or are already underway, with expectations for positive results to enhance investor returns [33] Strategic Focus - **Market Strategy**: The company emphasizes maximizing product value through strategic partnerships rather than merely pursuing business development [22] - **Future Directions**: Dize Pharmaceutical aims to explore new targets and non-oncological indications while ensuring existing product lines are fully developed [26] Conclusion - Dize Pharmaceutical is positioned for significant growth with its innovative drug pipeline, strong financial performance, and strategic market positioning, indicating a promising outlook for investors and stakeholders in the pharmaceutical industry.

Core Viewpoint - Hutchison China MediTech Limited (HCM) reported a total revenue of $278 million for the first half of 2025, a decrease of 9.16% year-on-year, while net profit attributable to shareholders surged to $455 million, reflecting a significant increase of 1663.32% [1] Financial Performance - Total revenue for HCM in the first half of 2025 was $278 million, down 9.16% compared to the previous year [1] - Net profit attributable to shareholders reached $455 million, marking a substantial increase of 1663.32% year-on-year [1] - Basic earnings per share for ordinary shares were reported at $0.53 [1] Strategic Developments - HCM's non-executive chairman, Dr. Dan Eldar, emphasized the company's strong financial position and operational strength, indicating readiness for a new growth phase [1] - The company is focusing on collaboration opportunities with multinational pharmaceutical companies, particularly in licensing deals with Chinese biotech firms [1] - HCM plans to deploy resources cautiously yet actively to accelerate the development of candidates from its innovative ATTC platform [1][2] Clinical and Regulatory Milestones - Significant milestones were achieved in the first half of 2025, including impressive data from the SACHI study presented at the ASCO annual meeting, demonstrating clinical benefits for patients with EGFR TKI-resistant lung cancer [1] - The approval for the drug Vorasertib was obtained ahead of expectations, allowing participation in this year's National Medical Insurance Drug List negotiations [1] - HCM's third indication for the drug Aiyoute for kidney cancer has been accepted by the National Medical Products Administration, with data to be presented at the ESMO annual meeting [1] Future Outlook - The company anticipates a rebound in sales growth in the second half of 2025, driven by the expansion of indications in China and increased penetration in overseas markets [2] - HCM is advancing multiple candidates from its key ATTC technology platform into clinical development, which is expected to enrich its product pipeline and create more collaboration opportunities [2]